Ramona Sequeira – President, Takeda Pharmaceuticals USA;…
Takeda USA’s Ramona Sequeira outlines her expanded role as president of global portfolio commercialization, the crucial importance of investing in…
Tagged with Rare Diseases
Bradley Campbell – President & COO, Amicus…
Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into…
Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…
Peter L. Saltonstall – President & CEO, National…
Ahead of the 2020 US National Organization for Rare Disorders (NORD)’s Rare Diseases and Orphan Products Breakthrough Summit, NORD president and CEO…
Paying for Cell & Gene Therapy in the USA: Is the Future…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…
Gary Zieziula – President & Region Head North America,…
Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the…
Kevin Houdenaert – General Manager, Recordati Benelux…
Kevin Houdenaert, general manager for Benelux and the Nordics at Italian rare disease, specialty and primary care specialist Recordati, gives an…
William H Lewis – Chairman & CEO, Insmed
William H Lewis, chairman and CEO of serious and rare disease specialist Insmed, talks through the impact of recent product approvals in the US,…
Bill Sibold – Executive Vice President, Sanofi Genzyme
Speaking exclusively to PharmaBoardroom, Sanofi Genzyme Executive VP Bill Sibold outlines Sanofi’s strategy for its specialty care unit, the wealth…
LFB USA CEO Optimistic on Hemophilia Launches Amid COVID Crisis
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new…
Korean Corestem Targets US Market for Ground-Breaking ALS…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the…
Kyung Suk Kim – CEO, Corestem
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea,…
